BBIO BridgeBio Pharma (BBIO) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001743881
Congress · 1Form 144 · 3
Insider buyers, 180 days
0
Funds added, last quarter
259
13F, latest reported quarter
Conversions, 180 days
18
Codes C/M, not in net · $5.6M priced
What the filings say about BBIO
Insiders, 180 days
-$40.6M net sold
7 sellers · 18% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-09-29
Planned sales (Form 144), 90 days
$7.0M
3 notices
BridgeBio Pharma insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BridgeBio Pharma, Inc. insiders sold a net $40.6M of stock across 280 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 155 earlier Form 4 trades (code P or S) here by this insider (155 sales), the last on Aug 19, 2026.
- The trade is 1.8% of the 496,965 shares held after it.
- No other insider sold within 30 days.
- 259 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Kumar Neil sold about $601.9K of BBIO under a 10b5-1 plan on Sep 17, 2026; 259 funds added in the latest 13F quarter.Context
- 155 earlier Form 4 trades (code P or S) here by this insider (155 sales), the last on Aug 19, 2026.
- The trade is 0.3% of the 495,686 shares held after it.
- No other insider sold within 30 days.
- 259 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Kumar Neil sold about $89.0K of BBIO under a 10b5-1 plan on Sep 17, 2026; 259 funds added in the latest 13F quarter.Context
- 152 earlier Form 4 trades (code P or S) here by this insider (152 sales), the last on Aug 18, 2026.
- The trade is 1.6% of the 507,586 shares held after it.
- 1 other insider sold within 30 days.
- 259 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Kumar Neil sold about $679.3K of BBIO under a 10b5-1 plan on Aug 19, 2026; 1 other insider sold within 30 days and 259 funds added in the latest 13F quarter.Context
- 152 earlier Form 4 trades (code P or S) here by this insider (152 sales), the last on Aug 18, 2026.
- The trade is 0.4% of the 505,786 shares held after it.
- 1 other insider sold within 30 days.
- 259 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Kumar Neil sold about $152.4K of BBIO under a 10b5-1 plan on Aug 19, 2026; 1 other insider sold within 30 days and 259 funds added in the latest 13F quarter.Context
- 152 earlier Form 4 trades (code P or S) here by this insider (152 sales), the last on Aug 18, 2026.
- The trade is 0.0% of the 505,686 shares held after it.
- 1 other insider sold within 30 days.
- 259 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Kumar Neil sold about $8.6K of BBIO under a 10b5-1 plan on Aug 19, 2026; 1 other insider sold within 30 days and 259 funds added in the latest 13F quarter.280 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$40.6M over 180 days
-$4.6M over 90 days
below 93% of Pharma & Biotech
Congress
1 member bought in the last year
the lowest in Pharma & Biotech
Funds
259 funds bought in last quarter
more than 94% of Pharma & Biotech
Revenue
+126.3% year over year
more than 86% of Pharma & Biotech
Margin
-146.0% net margin
below 62% of Pharma & Biotech
Buybacks
$210.0M repurchased, FY to 2026-06-30
more than 78% of Pharma & Biotech
Short interest
11.8% of the float short (float per yahoo 2026-10-26) · 5.8 days to cover · settled 2026-09-30
more than 71% of Pharma & Biotech
What changed in the last 30 days
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 13 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch BBIO
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+28.9%12M
Insider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BBIO: institutional holders (13F)
13F holdings, latest reported quarter
14,110,278 sh
$1.1B
13,260,971 sh
$987.7M
10,743,063 sh
$800.1M
10,287,156 sh
$766.2M
9,949,219 sh
$741.0M
Congress trades in BBIO
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-29 · disclosed 13 days later
$1,001 - $15,000
Bought 2026-05-11 · disclosed 28 days later
$1,001 - $15,000
Bought 2026-04-29 · disclosed 9 days later
$1,001 - $15,000
Bought 2026-03-19 · disclosed 19 days later
$1,001 - $15,000
Bought 2026-03-18 · disclosed 20 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BBIO planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019
Filed 2026-08-19
$2.5M
NEIL KUMAR
Filed 2026-08-18
$2.8M
RANDAL SCOTT
Filed 2026-08-17
$1.7M
ANDREA ELLIS
Filed 2026-07-09
$1.4M
JENNIFER COOK
Filed 2026-07-09
$13.2M
BBIO mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Franklin Genomic Advancements ETF
$977.8K position · as of 2026-06-30
3.5%
Miller Convertible Total Return ETF
$489.4K position · as of 2026-07-31
3.5%
Tema Oncology ETF
$4.8M position · as of 2026-05-31
2.8%
Franklin Convertible Securities Fund
$82.2M position · as of 2026-07-31
2.7%
Tema Heart & Health ETF
$1.3M position · as of 2026-05-31
2.6%
TETON Convertible Securities Fund
$336.9K position · as of 2026-06-30
2.5%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Bridgebio Pharma Inc. Pac (Bridgebiopac)
Cycle 2026 · $35K spent
$129.9K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Dr. Kumar
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$12.2M
$70.1M
$6.7M
+15%
+19%
2022
$6.7M
-$11.3M
$3.0M
-78%
+14%
2021
$25.6M
-$132.8M
$8.7M
-52%
+26%
2020
$10.1M
$151.1M
$4.8M
+103%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $40.6M sold by insiders over 180 days, 259 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade, $7.0M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
BBIO financials
Revenue growth
+126.3%
XBRL, annual
Net margin
-146.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$713.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BBIO
| FY Dec 2025 | $502.1M |
| FY Dec 2024 | $221.9M |
| FY Dec 2023 | $9.3M |
| FY Dec 2022 | $77.6M |
| FY Dec 2021 | $69.7M |
| Jun 2026 | $243.7M |
| Mar 2026 | $194.5M |
| Dec 2025 | $154.2M |
| Sep 2025 | $120.7M |
| Jun 2025 | $110.6M |
| Mar 2025 | $116.6M |
| Dec 2024 | $5.9M |
| Sep 2024 | $2.7M |
At each fiscal year end
Single quarter
Net margin, TTM
-98.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BBIO
| FY Dec 2025 | -146.0% |
| FY Dec 2024 | -244.9% |
| FY Dec 2023 | -7,022% |
| FY Dec 2022 | -624.1% |
| FY Dec 2021 | -841.2% |
| Jun 2026 | -64.0% |
| Mar 2026 | -85.6% |
| Dec 2025 | -126.2% |
| Sep 2025 | -153.2% |
| Jun 2025 | -166.2% |
| Mar 2025 | -145.4% |
| Dec 2024 | -4,546% |
| Sep 2024 | -6,012% |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$435.4M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BBIO
| FY Dec 2025 | -$447.0M |
| FY Dec 2024 | -$521.7M |
| FY Dec 2023 | -$529.0M |
| FY Dec 2022 | -$424.3M |
| FY Dec 2021 | -$511.2M |
| Jun 2026 | -$71.5M |
| Mar 2026 | -$197.3M |
| Dec 2025 | -$56.5M |
| Sep 2025 | -$110.0M |
| Jun 2025 | -$81.3M |
| Mar 2025 | -$199.2M |
| Dec 2024 | -$195.4M |
| Sep 2024 | -$180.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity BBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
-0.16x
TTM operating cash flow over LongTermDebt as filed 2026-06-30 (includes the current portion)
Cash flow to debt BBIO
| FY Dec 2025 | -0.22x |
| FY Dec 2024 | -1.18x |
| FY Dec 2023 | -1.17x |
| FY Dec 2022 | -0.97x |
| FY Dec 2021 | -1.15x |
| Jun 2026 | -0.16x |
| Mar 2026 | -0.17x |
| Dec 2025 | -0.22x |
| Sep 2025 | -0.29x |
| Jun 2025 | -179.87x |
| Mar 2025 | -137.25x |
| Dec 2024 | -1.18x |
| Sep 2024 | -1.02x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity BBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-61.1%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BBIO
| FY Dec 2025 | -79.0% |
| FY Dec 2024 | -74.1% |
| FY Dec 2023 | -111.7% |
| FY Dec 2022 | -59.3% |
| FY Dec 2021 | -68.3% |
| Jun 2026 | -61.1% |
| Mar 2026 | -64.8% |
| Dec 2025 | -79.0% |
| Sep 2025 | -96.9% |
| Jun 2025 | -83.8% |
| Mar 2025 | -78.2% |
| Dec 2024 | -74.1% |
| Sep 2024 | -67.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital BBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-80.9%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BBIO
| FY Dec 2025 | -74.1% |
| FY Dec 2024 | -101.6% |
| FY Dec 2023 | -134.4% |
| FY Dec 2022 | -74.3% |
| FY Dec 2021 | -77.6% |
| Jun 2026 | -80.9% |
| Mar 2026 | -81.8% |
| Dec 2025 | -74.1% |
| Sep 2025 | -93.3% |
| Jun 2025 | -83.9% |
| Mar 2025 | -97.1% |
| Dec 2024 | -101.6% |
| Sep 2024 | -101.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing BBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$15.5B
market value at close 2026-10-27 on 2026-08-03 shares, plus LongTermDebt as filed 2026-06-30 (includes the current portion), minus cash 2026-06-30
Enterprise value BBIO
| FY Dec 2025 | $16.2B |
| FY Dec 2024 | $4.9B |
| FY Dec 2023 | $7.1B |
| FY Dec 2022 | $1.2B |
| FY Dec 2021 | $2.5B |
| Jun 2026 | $16.6B |
| Mar 2026 | $16.2B |
| Dec 2025 | $16.2B |
| Sep 2025 | $11.3B |
| Jun 2025 | $7.5B |
| Mar 2025 | $6.0B |
| Dec 2024 | $4.9B |
| Sep 2024 | $5.0B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.2%
TTM free cash flow over market value at close 2026-10-27
FCF yield BBIO
| FY Dec 2025 | -3.0% |
| FY Dec 2024 | -10.1% |
| FY Dec 2023 | -7.5% |
| FY Dec 2022 | -37.3% |
| FY Dec 2021 | -20.8% |
| Jun 2026 | -3.0% |
| Mar 2026 | -3.1% |
| Dec 2025 | -3.0% |
| Sep 2025 | -5.9% |
| Jun 2025 | -8.0% |
| Mar 2025 | -7.6% |
| Dec 2024 | -10.1% |
| Sep 2024 | -9.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing BBIO
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $502.1M | $221.9M | $9.3M | $77.6M |
| Operating income | -$523.4M | -$593.0M | -$607.4M | -$512.2M |
| Net income | -$732.9M | -$543.3M | -$653.3M | -$484.6M |
| EPS (diluted) | -3.78 | -2.88 | -3.95 | -3.26 |
| Operating cash flow | -$445.9M | -$520.7M | -$527.7M | -$419.5M |
| Cash | $570.1M | $681.1M | $375.9M | $376.7M |
| Long-term debt | $2.0B | $437.3M | $446.4M | $431.0M |
| Buybacks | $48.3M | $0 | $0 | $0 |
SEC XBRL, fiscal years, as known on 2026-10-28
BBIO Stock Sonar score 6/7 axes
Find similar shapesCompareBBIO ranks highest on growth (86th percentile) and institutional and government (70th), and lowest on insider conviction (3rd), among Pharma & Biotech peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BBIO filings, in plain words
Are BridgeBio Pharma insiders buying or selling BBIO?
In the 180 days to 2026-10-28, BridgeBio Pharma insiders were net sellers, a net $40.6M across purchases and sales reported on Form 4, by 7 sellers.
Have members of Congress traded BBIO?
Yes. In the year to 2026-10-28, 1 House member disclosed buying BBIO and 1 House member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-09-29.
Are there planned insider sales of BBIO?
Yes. 3 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $7.0M of stock; the latest, by KUMAR HALDEA FAMILY IRREVOCABLE TRU/T/A DTD 05/18/2019, was filed 2026-08-19.
Read the full summary
In the 180 days to 2026-10-28, BridgeBio Pharma insiders were net sellers of BBIO, a net $40.6M across purchases and sales reported on Form 4 by 7 sellers. 18% of the 50 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. In the year to 2026-10-28, 1 member of Congress disclosed buying BBIO and 1 member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-09-29. Insiders filed 3 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $7.0M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
